Although the exact mechanism of interaction awaits further studies, our data suggest that it works at least partially via PARP1 trapping, raising the possibility that cancer cells with high expression of PARP1, even in a BRCA1/BRCA2-proficient scenario, may be particularly vulnerable to combined pevonedistat/PARPi treatments. The gene discussed is BRCA2; the disease is cancer.